Continuous Glucose Monitoring Thomas Repas D.O. Diabetes, Endocrinology and Nutrition Center, Affinity Medical Group, Neenah, Wisconsin Member, Inpatient.

Slides:

Advertisements

Similar presentations

Hanadi Baeissa Therapeutic Nutrition. Therapeutic nutrition = Medical nutrition therapy The role of food and nutrition in the treatment of various diseases.

Advertisements

Monitoring diabetes Diabetes Outreach (March 2011)

Diabetic Dermopathy Thomas Repas D.O. Diabetes, Endocrinology and Nutrition Center, Affinity Medical Group, Neenah, Wisconsin Member, Inpatient Diabetes.

A Formalized Patient Education Program for New Onset Diabetes 3NE/SW and 6NE Nurses R.D.’s in Food and Nutrition Dept. Theresa Pavone, MSN Rita Vercruysse,

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Diabetes Update: Living Life after Lente

Assessment and Management of Patients With Diabetes Mellitus Prepared by Dr. ImanAbdullah.

Afrezza® – inhaled human insulin

Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.

Effect of 21-day Holistic Therapy at “Our Native Village Eco Resorts” on Diabetes Mellitus as assessed by blood glucose levels and consumption of oral.

PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.

4-06 CHANGE IS GOOD: THE BASAL BOLUS INSULIN CONCEPT Management of Hyperglycemia in the Adult Hospitalized Patient TEAM MEMBERS: Physicians: Maryann Emanuele,

Module 3 Initial Recognition, Triaging, and Management of Hyperglycemia Diabetes Special Interest Group Georgia Hospital Association.

Presented by Dr. Soe Sandi Tint

Connected Health: Using patient-centric technologies to change behavior and improve outcomes Joseph C. Kvedar, MD Director Center for Connected Health.

Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.

Marta Alves, Celestino Neves, Ana Varela, Cristina Arteiro, Luís Miguel Pereira, Davide Carvalho, José Luís Medina. Endocrinology Service, S. João Hospital,

Achieving Glycemic Control in the Hospital Setting Part 4 of 4.

A Comparison of the Original vs. Modified Continuous Glucose Monitoring System (CGMS™) Sensor During Hypoglycemia in the Diabetes Research in Children.

Dr Stanley Ngare.  Pharmacology of Types of insulin available  Various routes of delivery & factors that affect absorption  Patient and provider barriers.

An Educational Service from GlycoMark

Prince Sattam Bin AbdulAziz University College Of Pharmacy Professor Mohammad Abd- elmotaal Mohammad Ruhal Ain, R Ph, PGDPRA, M Pharm Diabetes Mellitus.

Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)

The Physiological Variations of Plasma Glucose Concentrations in Healthy, Non-Diabetic Children: Use of Continuous Glucose Sensors Nelly Mauras, Roy Beck,

Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.

Diabetic Profile Measurement of Blood Glucose T.A. Bahiya Osrah.

Zainudin S 1, Ang DY 2, Goh SY 1, Soh AW 1. Department of Endocrinology, Singapore General Hospital, Singapore 1 ; Yong Loo Lin, School of Medicine, National.

Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Quality Improvement Strategies for Type.

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Pharmacy Protocol for Insulin Dosing in the Hospitalized Patient

EndoTool IV Physician User Guide Content Expert:

HbA1c before Ramadan (%)

Management of diabetes mellitus in hospitalized patients

Use of Insulin Pump in Children with Type I Diabetes Mellitus: Effect on glycemic control and Body Mass Indices (BMI). Noura Al Hemaidi, Maryam Al Ali,

Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2004 American Medical Association. All rights reserved.

Fig. 1. Scheme of the evaluation protocol

Placebo Metformin ***p < vs placebo

Canagliflozin: Real World Experience

W.S.T. Swarnasri1, Noel P. Somasundaram2

Endocrine System KNH 411.

Diabetes Health Status Report

Endocrine System KNH 411.

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Hemoglobin A1c Targets for Glycemic Controls

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Best Practices in Advanced Glucose Monitoring

Volume 70, Issue 8, Pages (October 2006)

Monitoring in Type 2 Diabetes

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Endocrine System KNH 411.

George Dailey, MD Mayo Clinic Proceedings

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Key Insulin Side Effects*

Endocrine System KNH 411.

Endocrine System KNH 411.

Endocrine System KNH 411.

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

Quality Management System

Assessing Diabetes Care at the Cornell Scott-Hill Health Center

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Blood glucose readings over time, with superimposed LOESS trend lines.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Glycemic control and body weight over 52 weeks.

Postoperative blood glucose levels and total insulin requirement.

Nutrition Interventions to Improve Quality of Care

Presentation transcript:

Continuous Glucose Monitoring Thomas Repas D.O. Diabetes, Endocrinology and Nutrition Center, Affinity Medical Group, Neenah, Wisconsin Member, Inpatient Diabetes Management Committee, St. Elizabeth’s Hospital, Appleton, WI Member, Diabetes Advisory Group, Wisconsin Diabetes Prevention and Control Program Website:

MiniMed Continuous Glucose Monitoring System (CGMS)

F Interstitial fluid glucose (G2) is almost always comparable with blood glucose (G1) Interstitial Fluid Measurement

Continuous Glucose Monitoring Midnight Noon Meal Type 1 Normal 2-day tracing

Elevated glycosylated hemoglobin (HbA1c)Elevated glycosylated hemoglobin (HbA1c) Hypoglycemic episodes and unawarenessHypoglycemic episodes and unawareness Hyperglycemic episodesHyperglycemic episodes Diabetic ketoacidosisDiabetic ketoacidosis Unexplained blood glucose excursionsUnexplained blood glucose excursions GastroparesisGastroparesis Gestational diabetes, preconception, pregnancy and nursingGestational diabetes, preconception, pregnancy and nursing Evaluation of therapeutic changes to medication regimenEvaluation of therapeutic changes to medication regimen Evaluation of behavioral modifications affecting glycemic controlEvaluation of behavioral modifications affecting glycemic control Patients undergoing erythropoietin therapy or with hemolytic disorders because HbA1c may be unreliablePatients undergoing erythropoietin therapy or with hemolytic disorders because HbA1c may be unreliable While the system may be used effectively with all diabetes patients, it may be of particular use in evaluating the following conditions and situations: CGMS Indications

Snapshot vs. Continuous 4 times/day

Snapshot vs. Continuous 288 times/day

CGMS Pilot Study HbA1c (%) Bode, et al., Diabetes Research and Clinical Practice, 1999, 46: p=0.0006p=0.021, from Baseline N=9